Tonix Pharmaceuticals Holding Corp.

NasdaqCM:TNXP Stock Report

Market Cap: US$114.3m

Tonix Pharmaceuticals Holding Past Earnings Performance

Past criteria checks 0/6

Tonix Pharmaceuticals Holding's earnings have been declining at an average annual rate of -26.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 91.9% per year.

Key information

-26.1%

Earnings growth rate

75.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate91.9%
Return on equity-182.3%
Net Margin-1,197.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Tonix Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:TNXP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411-1353649
30 Jun 2412-1493761
31 Mar 2410-993773
31 Dec 238-1173587
30 Sep 234-1233194
30 Jun 230-1243095
31 Mar 230-1233090
31 Dec 220-1173082
30 Sep 220-1122979
30 Jun 220-1022770
31 Mar 220-982672
31 Dec 210-922369
30 Sep 210-802159
30 Jun 210-731954
31 Mar 210-641747
31 Dec 200-521436
30 Sep 200-461230
30 Jun 200-421226
31 Mar 200-341119
31 Dec 190-311118
30 Sep 190-311018
30 Jun 190-281016
31 Mar 190-29916
31 Dec 180-29918
30 Sep 180-24816
30 Jun 180-24817
31 Mar 180-23816
31 Dec 170-21813
30 Sep 170-23915
30 Jun 170-25915
31 Mar 170-30921
31 Dec 160-391029
30 Sep 160-451233
30 Jun 160-501339
31 Mar 160-521339
31 Dec 150-481336
30 Sep 150-441232
30 Jun 150-381127
31 Mar 150-321022
31 Dec 140-28919
30 Sep 140-22814
30 Jun 140-18711
31 Mar 140-1477

Quality Earnings: TNXP is currently unprofitable.

Growing Profit Margin: TNXP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TNXP is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.

Accelerating Growth: Unable to compare TNXP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TNXP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: TNXP has a negative Return on Equity (-182.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tonix Pharmaceuticals Holding Corp. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
James MolloyAlliance Global Partners
David BuckB. Riley Securities, Inc.